Clinical Trial Update: Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib for patients with advanced, refractory cancer harboring KIT mutation or amplification.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced, Refractory Cancer | Phase 2 | Status: UNKNOWN